CellMax Life Appoints Dr. Ross D. “Rusty” Segan to Advisory Board
SUNNYVALE, Calif. (PRWEB) August 02, 2023 -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer (CRC) screening blood test, that also detects pre-cancerous polyps, or adenomas, today announced the appointment of Dr. Ross D. Segan as an advisory board member.
“Rusty is a visionary in aligning science, medicine and technology, bringing innovations that are clinically relevant into real-life healthcare settings,” said Atul Sharan, CEO of CellMax Life. “His clinical background and executive experience in minimally invasive technologies, particularly in the field of gastroenterology, will help CellMax drive engagement with the medical community and regulatory authorities on the clinical efficacy and utility of our FirstSight™ test.”
Dr. Segan is a leader in the medical technology industry, most recently serving as Global Chief Medical Officer at Olympus Corporation, the world’s largest innovator and developer of gastroenterology medical technologies with over 70% of the global market for gastrointestinal endoscopes. He also served as Chief Medical Officer at Johnson & Johnson and Covidien Surgical Solutions (acquired by Medtronic). Prior to his medical executive career, Dr. Segan was a highly regarded surgeon at the University of Maryland Medical Center. Dr. Segan also served in the U.S. Army as Chief of Minimally Invasive Surgery at the Tripler Army Medical Center, where he performed minimally invasive procedures on troops in Afghanistan until he medically retired from injuries sustained during a combat medevac mission.
“CRC is a preventable cancer, and despite the currently available non-invasive stool tests and the use of colonoscopy for screening, it continues to be the second deadliest cancer in the US,” said Dr. Segan. “To structurally change this, we need a blood test that can detect early-stage cancer and adenomas with high enough sensitivity. The FirstSight blood test has repeatedly demonstrated the ability to detect advanced adenomas and CRC with high sensitivity and has the potential to eradicate colon cancer.”
For more information about CellMax Life and its FirstSight test, visit cellmaxlife.com.
About CellMax Life
CellMax Life is a molecular diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California. For more information, visit http://www.cellmaxlife.com.
Stephen Su, CellMax Life, http://www.cellmaxlife.com, 1 4088877640, [email protected]
Share this article